Home » Topics » Disease categories and therapies » Ocular

Ocular
RSS

Macugen now available

Jan. 25, 2005

Jerini and Alcon collaborate on novel ophthalmology drugs

Jan. 24, 2005

Phase II study evaluates recombinant microplasmin in vitreoretinal disorders

Jan. 21, 2005

Evidence suggests that retinitis pigmentosa may be caused by mutations in the CA4 gene

Jan. 17, 2005

Phase II data on the efficacy of squalamine in wet AMD

Jan. 13, 2005

ISTA launches Vitrase

Jan. 11, 2005

Squalamine selected for CMA Pilot 2 program

Jan. 10, 2005

Macugen approved for neovascular AMD

Dec. 21, 2004

Alcon completes NDA filing for Retaane

Dec. 21, 2004

rEV-131 for postcataract surgery impresses in preclinical study

Dec. 20, 2004

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...